Sun Pharmaceutical Industries

Latest news

• Pfizer Sues Sun Pharmaceutical to Block Copies of Cancer Drug (opens in a new tab)

  Bloomberg Law News · Oct 2, 2026

• Sun Pharma's Leqselvi shows sustained hair regrowth through two years in alopecia areata (opens in a new tab)

  The Pharma Letter · Oct 2, 2026

• Sun Pharma's US Business Under Pressure: Can New Launches Drive a Recovery? (opens in a new tab)

  Trade Brains · Oct 2, 2026

• Sun Pharma Publishes Postal Ballot and E-Voting Notices for Shareholders (opens in a new tab)

  TipRanks · Oct 2, 2026

• Sun Pharma Postal Ballot Notice October 2026 (opens in a new tab)

  Kalkine India · Oct 2, 2026

• Sun Pharma seeks approval for ESOP 2026 and ₹700 billion borrowing limit (opens in a new tab)

  scanx.trade · Oct 1, 2026

• Sun Pharma (NSE: SUNPHARMA) Secures Global Rights for Lerodalcibep Outside the US and China (opens in a new tab)

  Kalkine India · Oct 1, 2026

• Sun Pharma reports sustained LEQSELVI efficacy in two-year alopecia study (opens in a new tab)

  scanx.trade · Oct 1, 2026

• Sun Pharma’s LEQSELVI shows sustained hair regrowth through two years (opens in a new tab)

  Indian Pharma Post · Oct 1, 2026

• 
  New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026 (opens in a new tab)

  PR Newswire · Oct 1, 2026

• Sun Pharmaceutical Industries slips Thursday, still outperforms market (opens in a new tab)

  MarketWatch · Oct 1, 2026

• Sun Pharma’s Biggest Global Bet, Buys Organon in $11.75 Billion Deal; Pharma Stock Surge 7% - Time to Buy? (opens in a new tab)

  Goodreturns · Oct 1, 2026

• Sun Pharmaceutical Industries slips Wednesday, underperforms market (opens in a new tab)

  MarketWatch · Sep 30, 2026

• India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say (opens in a new tab)

  Reuters · Sep 29, 2026

• Sun Pharmaceutical Industries rises Tuesday, outperforms market (opens in a new tab)

  MarketWatch · Sep 29, 2026

• 
  LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU (opens in a new tab)

  Business Wire · Sep 28, 2026

• Sun Pharmaceutical Industries falls Monday, underperforms competitors (opens in a new tab)

  MarketWatch · Sep 28, 2026

• Sun Pharmaceutical Industries (NSEI:SUNPHARMA) Stock Forecast & Analyst Predictions (opens in a new tab)

  Simply Wall Street · Sep 28, 2026

• Sun Pharma in focus after tapping into $3.7 Billion ex-US/China PCSK9 inhibitor market (opens in a new tab)

  Trade Brains · Sep 28, 2026

• Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Secures Lerodalcibep Rights Across Global Markets (opens in a new tab)

  Kalkine India · Sep 28, 2026

• Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep (opens in a new tab)

  Daily Excelsior · Sep 28, 2026

• Sun Pharma shareholders approve reclassification of promoters to public (opens in a new tab)

  scanx.trade · Sep 26, 2026

• Sun Pharmaceutical Industries rises Friday, underperforms competitors (opens in a new tab)

  MarketWatch · Sep 25, 2026

• SUNPHARMA Outlook for the Week (September 28, 2026 – October 02, 2026) (opens in a new tab)

  Equitypandit · Sep 25, 2026

• Sun Pharma के शेयर में हल्की बढ़त, ILUMYA के नए arthritis उपयोग की US FDA समीक्षा मंजूरी के बाद। (opens in a new tab)

  Alice Blue · Sep 24, 2026

• Sun Pharma Investor Presentation: Growth, Market Leadership & Strategy (opens in a new tab)

  investywise.com · Sep 22, 2026

• Sun Pharmaceutical Industries falls Tuesday, underperforms market (opens in a new tab)

  MarketWatch · Sep 22, 2026

• Sun Pharma FY26 Results: Net profit up 5% YoY to ₹11,479 crore (opens in a new tab)

  scanx.trade · Sep 22, 2026

• 
  Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight (opens in a new tab)

  GlobeNewswire · Sep 21, 2026

• Brokerage ‘Buy’ Calls: Phoenix Mills To Sun Pharma; Top 4 Stocks With Up To 30% Uptick Potential (opens in a new tab)

  The Daily Jagran · Sep 21, 2026